Hospira

J.P. Morgan recently met with Hospira's (NYSE: HSP) management team “and wanted to share our quick takeaways and highlights from the discussion.” “Specifically, we remain upbeat about generic Taxotere dynamics and comfortable with our above guidance forecast of $4.05 for 2011 EPS,” J.P. Morgan...

Goldman Sachs is moving to the sidelines on Hospira (NYSE: HSP). “Our long-term bias remains positive; however, we see better opportunities elsewhere and few near-term catalysts until the company's September 2011 analyst meeting,” Goldman Sachs writes. “In addition, we think the company will need...

J.P. Morgan, which raised its PT on shares of Hospira Inc. (NYSE: HSP), is providing some color on the stock. “Hospira kicked off its 2011 with a strong 1Q ($0.93, +$0.10 vs. JPMe) on better-than-expected performance in both its specialty injectable and device businesses,” J.P. Morgan writes. “We...

JP Morgan has raised the price target on Hospira (NYSE: HSP) from $64 to $66 and maintains its Overweight rating.

Citigroup has downgraded Hospira (NYSE: HSP) from Hold to Sell and has raised the price target from $52 to $54.

1Q11 IMS sales are improving for Hospira Inc. (NYSE: HSP), Morgan Stanley reports. “On a reported basis, total Hospira IMS sales were down 4% y/y QTD 1Q11m,” Morgan Stanley writes. “However, sales were up 23% y/y and 16% vs 4Q10 (excluding oxaliplatin) with recent launches (Zosyn and gemcitabine)...

Morgan Stanley has increased its first quarter estimates for Hospira (NYSE: HSP). According to the report, “We are increasing our 1Q EPS estimate to $0.79 from $0.65 and revenues from $893MM to $939MM more or less in-line with the updated guidance. For the full year, our EPS estimate rises to $4....

In a report published by Goldman Sachs, Hospira (NYSE: HSP) has a new CEO in place, with fundamental catalysts up next. Goldman Sachs said that, in addition to the company's appointment of Michael Ball (currently President of Allergan) to the CEO role, it sees two upcoming fundamental catalysts...

Citigroup has upgraded Hospira (NYSE: HSP) from Sell to Hold and has lowered the price target from $53 to $52.

Goldman Sachs is out with its report on Hospira (NYSE: HSP), lowering its price target from $65 to $59. In a note to clients, Goldman Sachs writes, "Following Hospira's 4Q2010, we lower EPS forecasts for 2011-2014 to $3.93/$4.53/$5.06/$5.52 from $4.32/$5.01/$5.60/$6.07 on the basis of lower...